Some modules are disabled because cookies are declined. Accept cookies to experience the full functionality of this page.
ACCEPT COOKIES
Media Contacts
photo:Newgate  Communications
Newgate Communications
Alistair Kellie and Andrew Adie
tel: 0207 680 6550
e-mail:
Poll
Bedankt voor uw stem!
Social media
banner
York, 13 May 2013

Tissue Regenix Group plc ("Tissue Regenix" or "the Group"), the regenerative medical devices company which uses animal or human tissue to replace damaged or worn out parts of the human body, today announces its unaudited preliminary results for the year ended 31 January 2013.

 

Operational Highlights

During the year, Tissue Regenix has:

·      Completed a successful pre-clinical study for dCELL® meniscus

·      Established its US subsidiary in order to target its growing regenerative medicine market

·      Added patents related to 'Acellular Arteries' to global exclusive licence portfolio

·      Produced positive interim clinical data for its dCELL® Dermis technology

·      Demonstrated a strong safety profile and effectiveness of its vascular patch in results from two year clinical study

·      Made a number...

 Read more from this release
button previous button next icon more headlines icon RSS
02 May 2013 -

New skin graft heals chronic leg ulcers

Read more
16 Apr 2013 -

Approval given for start of clinical research trial to examine the ..

Read more
02 Apr 2013 -

Tissue Regenix makes another senior appointment to its US subsidiar..

Read more
14 Feb 2013 -

Successful pre-clinical study for dCELL® meniscus

Read more
30 Nov 2012 -

Tissue Regenix board changes

Read more